stockportfolio.pro
Pacira BioSciences, Inc. P/E Ratio 2009–2025
Pacira BioSciences, Inc. (PCRX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -14.3%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 161.75 | — |
| FY 2024 | — | — |
| FY 2023 | 37.91 | -66.6% |
| FY 2022 | 113.56 | +73.6% |
| FY 2021 | 65.40 | +264.0% |
| FY 2020 | 17.97 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | 1919.75 | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Pacira BioSciences, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Pacira BioSciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freePacira BioSciences, Inc. — frequently asked questions
What is Pacira BioSciences, Inc.'s price-to-earnings ratio?
Pacira BioSciences, Inc. (PCRX) reported price-to-earnings ratio of 161.75 for fiscal year 2025, per its SEC filings.
How has Pacira BioSciences, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, PCRX's price-to-earnings ratio declined at roughly 14.3% per year (compound annual rate), from 1919.75 to 161.75.
Where does this data come from?
Figures are computed from Pacira BioSciences, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.